CJC-1295 (No DAC)

CJC-1295 (No DAC) Peptide – 5mg
CJC-1295 (No DAC) is a synthetic growth hormone-releasing hormone (GHRH) analog consisting of 30 amino acids. It is designed to bind GHRH receptors on pituitary somatotrophs, stimulating pulsatile growth hormone (GH) release and subsequent insulin-like growth factor 1 (IGF-1) production. The “No DAC” designation indicates the absence of a drug affinity complex (DAC) modification, resulting in a shorter half-life and use primarily for experimental protocols requiring controlled, pulsatile GH stimulation rather than sustained elevation.

Overview
CJC-1295 (No DAC) was developed by modifying native GHRH(1-29) with four amino acid substitutions (positions 2, 8, 15, and 27) to increase stability against enzymatic degradation. Without DAC conjugation, this peptide has a relatively short plasma half-life, favoring physiologic GH release patterns. It is commonly studied alongside growth hormone secretagogues (GHS) like Ipamorelin or GHRP analogs for synergistic research in metabolism, body composition, and regenerative medicine models.

Chemical Makeup

• Molecular Formula: C152H252N44O42
• Molecular Weight: 3355.9 g/mol
• Amino Acid Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Gln-Lys-Gln-Gln-Gly-Glu-Ser
• Compound Class: GHRH analog, tetrasubstituted, No DAC modification
• Purity: ≥99% (per COA)
• Amount: 5mg per vial

Research and Clinical Studies

Growth Hormone Stimulation
CJC-1295 (No DAC) retains high receptor affinity for GHRH receptors, stimulating GH release in a physiologic, pulsatile manner. Preclinical studies confirm dose-dependent GH secretion without persistent elevation, mimicking natural GH rhythms.

Metabolic and Body Composition Studies
Research indicates CJC-1295 increases serum GH and IGF-1, supporting studies on fat metabolism, lean mass maintenance, and glucose regulation. Combination with GHS peptides like Ipamorelin has been shown to amplify GH pulse amplitude.

Neurological and Regenerative Research
GH and IGF-1 pathways are known to influence neurogenesis, wound healing, and connective tissue remodeling. CJC-1295 (No DAC) provides a controlled model to study these effects.

Pharmacokinetics
Unlike DAC-modified CJC-1295, which binds serum albumin for extended half-life, CJC-1295 (No DAC) is rapidly cleared, allowing precise experimental timing of GH stimulation.

CJC-1295 (No DAC) is available for research and laboratory purposes only. Not for human consumption.

References

1. Teichman SL, et al. CJC-1295, a long-acting GHRH analog: safety and pharmacokinetics. J Clin Endocrinol Metab. 2006;91(3):799–805. https://pubmed.ncbi.nlm.nih.gov/16352683/
2. Frohman LA, et al. Growth hormone-releasing hormone: discovery and clinical relevance. Endocr Rev. 2000;21(1):1–47. https://pubmed.ncbi.nlm.nih.gov/10696565/
3. Lapierre H, et al. CJC-1295 increases plasma IGF-1 in primate studies. Endocrinology. 2005;146(6):3052–3058. https://pubmed.ncbi.nlm.nih.gov/15746190/
4. Pihoker C, et al. Growth hormone dynamics and feedback regulation. J Clin Endocrinol Metab. 1998;83(10):3417–3421. https://pubmed.ncbi.nlm.nih.gov/9768658/
5. Bowers CY. Discovery of growth hormone-releasing peptides. Endocr Rev. 1998;19(6):801–822. https://pubmed.ncbi.nlm.nih.gov/9861543/
6. Müller EE, et al. Hypothalamic control of GH secretion. Physiol Rev. 1999;79(2):511–607. https://pubmed.ncbi.nlm.nih.gov/10221987/
7. Popovic V, et al. GH secretagogues and GHRH analogs in clinical research. J Endocrinol Invest. 2003;26(9):872–881. https://pubmed.ncbi.nlm.nih.gov/14628911/
8. Jansson JO, et al. Pulsatile GH release and experimental regulation. Endocr Rev. 1985;6(2):128–150. https://pubmed.ncbi.nlm.nih.gov/2861011/
9. Strasburger CJ, et al. GH and IGF-1 actions in tissue repair. Growth Horm IGF Res. 2000;10 Suppl B:S6–S8. https://pubmed.ncbi.nlm.nih.gov/10984265/
10. Bowers CY, et al. Synergistic GH release with GHRH analogs and GHS peptides. J Clin Endocrinol Metab. 1990;70(4):975–982. https://pubmed.ncbi.nlm.nih.gov/2318961/